Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells $226,611.33 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,729 shares of GeneDx stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $226,611.33. Following the sale, the chief financial officer directly owned 39,954 shares in the company, valued at $2,428,004.58. The trade was a 8.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, June 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $53.77, for a total transaction of $68,072.82.
• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The shares were sold at an average price of $65.19, for a total value of $25,554.48.

GeneDx Stock Performance

GeneDx stock opened at $59.01 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The stock has a fifty day moving average price of $54.25 and a two-hundred day moving average price of $86.49. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The firm has a market capitalization of $1.75 billion, a P/E ratio of -22.02 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last issued its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same quarter in the prior year, the firm posted ($0.23) EPS. As a group, analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on WGS. Guggenheim reduced their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Wells Fargo & Company restated an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Craig Hallum reaffirmed a “buy” rating and set a $85.00 price target on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Institutional Trading of GeneDx

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System grew its holdings in GeneDx by 2.1% during the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after buying an additional 113 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock worth $329,000 after buying an additional 142 shares in the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after buying an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock valued at $399,000 after acquiring an additional 181 shares during the period. Finally, Jones Financial Companies Lllp boosted its position in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the period. 61.72% of the stock is owned by institutional investors.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Multiple law firms are advertising a securities class action against GeneDx, with a lead-plaintiff deadline of August 3, 2026, alleging material misstatements and omissions about the viability of the Fabric Genomics acquisition. GeneDx securities fraud class action lawsuit filed
• Negative Sentiment: Several follow-up notices emphasize the alleged 49% stock decline after GeneDx’s Q1 2026 earnings report and a 94% write-off related to the acquisition, reinforcing concerns about execution and disclosure risk. Hagens Berman class action alert
• Neutral Sentiment: GeneDx disclosed insider sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to cover tax withholding obligations tied to vesting equity awards, which makes the transactions less alarming on their own. CEO SEC filing CFO SEC filing
• Positive Sentiment: GeneDx appointed Mark Gardner as company president, a leadership move that could improve execution and strategic focus over time. GeneDx appoints new president

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.